Litcius/Paper detail

Anti-rheumatic in SARS-CoV-2: benefit or risk?

Francesco Ferrara

2020Italian Journal of Medicine31 citationsDOIOpen Access PDF

Abstract

Not available

Topics & Concepts

MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyIntensive care medicineInternal medicineOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Anti-rheumatic in SARS-CoV-2: benefit or risk? | Litcius